posted on 2021-09-08, 22:01authored byNeetu Srivastava, Hao Hu, Anthony N. Vomund, Orion J. Peterson, Rocky L. Baker, Kathryn Haskins, Luc Teyton, Xiaoxiao Wan, Emil R. Unanue
Recognition of beta-cell antigens
by autoreactive T cells is a critical step in the initiation of autoimmune
Type1 diabetes (T1D). A complete protection from diabetes development in non-obese
diabetic (NOD) mice harboring a point mutation in the insulin B-chain 9-23
epitope points to a dominant role of insulin in diabetogenesis. Generation of
NOD mice lacking the Chromogranin A protein (NOD.ChgA-/-)completely nullified the autoreactivity of the BDC2.5 T cell and conferred
protection from diabetes onset. These results raised the issue concerning the
dominant antigen that drives the autoimmune process. Here we revisited the NOD.ChgA-/- mice
and found that their lack of diabetes development may not be solely explained
by the absence of Chromogranin A reactivity. NOD.ChgA-/- mice displayed
reduced presentation of insulin peptides in the islets and periphery, which corresponded
to impaired T cell priming. Diabetes
development in these mice was restored by antibody treatment targeting
regulatory T cells or inhibiting TGFb and PD-1 pathways. Therefore, the global
deficiency of chromogranin A impairs recognition of the major diabetogenic
antigen insulin, leading to broadly impaired autoimmune responses controlled by
multiple regulatory mechanisms.
Funding
This study is supported by grants from NIH (DK058177 and AI114551), Juvenile Diabetes Research Foundation, and Kilo Diabetes and Vascular Research Foundation.